Data Supports Safety Record Of ENBREL(R) As Continuous Therapy In Children And Adolescents With Juvenile Idiopathic Arthritis

Wyeth announced study results from last week’s 15th Paediatric Rheumatology European Congress (PRES) in London which highlight the safety record of etanercept (ENBREL(R)) as a continuous therapy in children and adolescents with juvenile idiopathic arthritis (JIA).(1) The study was designed to evaluate the safety of ENBREL in children with polyarticular or systemic JIA.

More: continued here

Filed under: Arthritis on September 30th, 2008